205 completed, 40 terminated, 26 recruiting, 23 unknown. 180 Phase 2, 85 Phase 1, 56 Phase 3, 12 Not applicable, 12 Phase 4.
Follow pegfilgrastim: new trials by email Literature Review of pegfilgrastim trials Research Report on pegfilgrastim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Medical College of Wisconsin | 31 | 2026-06-01 | 2026-08-25 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-05-13 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy Pegfilgrastim (Neulasta) - Triple-Negative Breast Cancer | Not applicable | Recruiting | Yonsei University | 40 | 2025-10-28 | 2026-04-20 |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation Plerixafor, Gcsf - Multiple Myeloma, Hodgkin Lymphoma | Phase 2 | Recruiting | Thomas Jefferson University | 100 | 2025-10-16 | 2025-11-28 |
| Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer Sacituzumab Govitecan with pegfilgrastim - Breast Cancer Metastatic | Phase 2 | Recruiting | Yeon Hee Park | 40 | 2025-07-03 | 2025-08-28 |
| Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies Spedox-6, Pegfilgrastim, Filgrastim - Soft-tissue Sarcoma, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 67 | 2025-04-30 | 2026-07-17 |
| Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas PEEL-224, Temozolomide, Vincristine - Sarcoma, Sarcoma, Ewing | Phase 1 / Phase 2 | Recruiting | David S Shulman, MD | 63 | 2025-01-27 | 2026-02-19 |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. TORL-1-23, Pegfilgrastim (drug) - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 230 | 2024-11-20 | 2025-12-23 |
| A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers PEG-MetHuG-CSF, Neulasta (Amgen) - PK in Healthy Volunteers | Phase 1 | Completed | PharmaEssentia | 30 | 2024-08-19 | 2025-06-29 |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma Dexrazoxane, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 324 | 2024-08-15 | 2026-09-23 |
| Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients Etoposide, Cytarabine, Pegfilgrastim - Multiple Myeloma, Hematopoietic Stem Cell Mobilization | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 99 | 2024-08-01 | 2024-07-25 |
| Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor - RUNX1 Familial Platelet Disorder | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 4 | 2024-05-20 | 2026-06-11 |
| Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease Vincristine, Dactinomycin, Cyclophosphamide - Rhabdomyosarcoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 135 | 2024-03-13 | 2026-06-15 |
| Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Cyclophosphamide, Vincristine, Blinatumomab - Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 27 | 2023-07-14 | 2026-09-23 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
Showing 20 of 321. Sign in to see all of them.
Breast Neoplasms (66) · Neutropenia (36) · Lymphoma (35) · Lymphoma, Large B-Cell, Diffuse (23) · Lymphoma, Non-Hodgkin (18) · Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (14) · Hodgkin Disease (13) · Ovarian Neoplasms (13) · Multiple Myeloma (11) · Sarcoma (11) · Burkitt Lymphoma (10) · Leukemia (10) · Lymphoma, Follicular (10) · Lymphoma, Mantle-Cell (10)
M.D. Anderson Cancer Center (19) · National Cancer Institute (NCI) (19) · Amgen (17) · Memorial Sloan Kettering Cancer Center (10) · St. Jude Children's Research Hospital (9) · Gynecologic Oncology Group (7) · Alliance for Clinical Trials in Oncology (5) · Mayo Clinic (5) · Washington University School of Medicine (5) · BeyondSpring Pharmaceuticals Inc. (4) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (4) · Children's Oncology Group (4) · Coherus Oncology, Inc. (4) · Eli Lilly and Company (4) · Sandoz (4)
United States (206) · Canada (25) · United Kingdom (22) · Australia (19) · France (16) · Germany (16) · Poland (13) · South Korea (13) · Spain (13) · Netherlands (12) · Russia (12) · Italy (11) · Ukraine (11) · Belgium (10) · China (9)
Barbara Finck, MD (3) · Dimitris Mavrudis, MD (3) · Anas Younes, MD (2) · Andrew D. Zelenetz, MD, PhD (2) · Edward A. Neuwelt, MD (2) · Elias Jabbour (2) · Giles W. Robinson, MD (2) · Jeffrey Crawford, MD (2) · Leona A. Holmberg, MD, PhD (2) · Martee Hensley (2)
PMID 35034311, PMID 25851633, PMID 28637287, PMID 32450725, PMID 40135712, PMID 15659500, PMID 15718314, PMID 15880129, PMID 17264331, PMID 17317205, PMID 17439836, PMID 18165618, PMID 18268285, PMID 18474099, PMID 18500375, PMID 18534250, PMID 18616811, PMID 18827613, PMID 19059939, PMID 19169289, PMID 19596586, PMID 19602710, PMID 19771508, PMID 20007996, PMID 20045791, PMID 20118030, PMID 20934233, PMID 21144560, PMID 21298497, PMID 21343560, PMID 21507583, PMID 21756035, PMID 21766209, PMID 21976055, PMID 22180164, PMID 22337718, PMID 22363068, PMID 22868240, PMID 23169503, PMID 23278639, PMID 23340294, PMID 23640206, PMID 24100924, PMID 24166522, PMID 24342730, PMID 24458437, PMID 24485296, PMID 24618336, PMID 24821883, PMID 25057177
U10CA027469 (8), U10CA180868 (4), 2016 (3), U10CA021115 (3), U10CA031946 (3), U10CA032102 (3), U10CA180821 (3), U10CA180886 (3), 2014 (2), P30CA006973 (2), P30CA015083 (2), P30CA033572 (2), P30CA036727 (2), U01CA070019 (2), U10CA045809 (2)